Faculty Information - Tomohiko Kimura

（Last updated : 2025-09-13 15:46:38）

Tomohiko Kimura
Department Kawasaki Medical School Kawasaki Medical School, Department of Diabetes, Endocrinology and Metabolism,

Position Assistant Professor

■ Journal Articles

1.	2025/08/07	Diabetic Ketoacidosis Associated with Non-occlusive Mesenteric Ischemia in a Subject with Type 2 Diabetes Mellitus: A Case Report
2.	2025/06/28	A clinical model for highly accurate prediction of blood glucose depression after continuous intravenous insulin therapy in hyperglycemic emergencies: A multicenter retrospective cohort study.
3.	2025/06/23	Primary Hyperparathyroidism Due to an Ectopic Parathyroid Adenoma Located in the Posterior Part of the Esophagus
4.	2025/06/11	Rhabdomyolysis triggered by initiation of tirzepatide: A case report
5.	2025/06/03	Development of a prediction model by combining tumor diameter and clinical parameters of adrenal incidentaloma
6.	2025/05/26	A case of exacerbation of Graves' disease triggered by BNT162b2 vaccination
7.	2025/05/23	Clinical characteristics of patients with hyperglycemic hyperosmolar state and/or diabetic ketoacidosis: single-center retrospective observational study.
8.	2025/04/01	Handgrip strength in patients with type 2 diabetes correlates with diabetic polyneuropathy. A single-center, retrospective observational study in Japanese patients.
9.	2025	A case of Haily-Haily disease accompanied by Cushing's syndrome and adrenal insufficiency due to long-term usage of topical steroids.
10.	2025	Evaluation of short-term knowledge change through a diabetes education program at Kawasaki Medical School Hospital
11.	2022/12/01	A Case of Central Diabetes Insipidus due to Igg4-related Hypophysitis that Required Over One Year to Reach the Final Diagnosis due to Symptoms Being Masked by Sialadenitis
12.	2022/04	Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
13.	2022/03/15	A case of prominent and persistent hypoglycemia by massive dose administration of long-acting insulin degludec: A possible pitfall in diabetes care.
14.	2022/03	Molecular Mechanism of Pancreatic β-Cell Failure in Type 2 Diabetes Mellitus
15.	2022/02	Metformin induces insulin secretion by preserving pancreatic aquaporin 7 expression in type 2 diabetes mellitus
16.	2022/01	Vitamin D deficiency osteomalacia triggered by long-term social withdrawal and unbalanced diet in a Japanese middle-aged subject: A case report
17.	2021/12	Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study
18.	2021/12	Syndrome of inappropriate secretion of thyroid-stimulating hormone in a subject with galactorrhea and menstrual disorder and undergoing infertility treatment
19.	2021/10	Amelioration of hypercalcemia by cinacalcet treatment in a subject with relapsing acquired hypocalciuric hypercalcemia: A case report
20.	2021/10	Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency
21.	2021/09	Idiopathic bilateral extraocular myositis in a subject with poorly controlled type 2 diabetes mellitus:Case report
22.	2021/08	Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
23.	2021/07	Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine
24.	2021/06/25	Case Report: Malignant Pheochromocytoma Without Hypertension Accompanied by Increment of Serum VEGF Level and Catecholamine Cardiomyopathy
25.	2021/06/09	A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time
26.	2021/06	Case Report: Malignant Pheochromocytoma Without Hypertension Accompanied by Increment of Serum VEGF Level and Catecholamine Cardiomyopathy
27.	2021/03/17	Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
28.	2021/03/05	Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History
29.	2020/12/11	Notable Underlying Mechanism for Pancreatic β-Cell Dysfunction and Atherosclerosis: Pleiotropic Roles of Incretin and Insulin Signaling
30.	2020/11/20	Comparison in effects by three kinds of glucose-lowering drugs on nonalcoholic fatty liver disease in cases with type 2 diabetes: A randomized, open-label, 3-arm active-control study.
31.	2020/08	Insulin allergy brought out 8 years after starting insulin therapy in a subject with type 1 diabetes mellitus
32.	2020/05/20	Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice
33.	2020/05	New prospects for incretin-related drugs in the treatment of type 2 diabetes
34.	2019/09	Decreased plasma aldosterone levels in patients with type 2diabetes mellitus: A possible pitfall in diagnosis of primary aldosteronism.
35.	2019/07	Vascular endothelial PDPK1 plays a pivotal role in the maintenance of pancreatic beta cell mass and function in adult male mice
36.	2019/03	Verification of Kumamoto Declaration 2013 and Glycemic Targets for Elderly Patients with Diabetes in Japan for prevention of diabetic complications: A retrospective longitudinal study using outpatient clinical data.
37.	2019/01	Association of the Glycemic Fluctuation as well as Glycemic Control with the Pancreatic beta-cell Function in Japanese Subjects with Type 2 Diabetes Mellitus.
38.	2019/01	Suppression of free fatty acid receptor 1 expression in pancreatic beta-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1
39.	2018/11	Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
40.	2018/10	Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in db/db mice: The earlier and longer, the better.
41.	2018/08	Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity
42.	2018/08	There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study.
43.	2018/06	Decreased plasma aldosterone levels in patients with type 2 diabetes mellitus: A possible pitfall in diagnosis of primary aldosteronism
44.	2018/06	Durability of protective effect of dulaglutide on pancreatic beta -cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
45.	2018/06	Onset of type 1 diabetes mellitus and heparin-induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome.
46.	2018/06	Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
47.	2018/02	Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism
48.	2018/01	Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus.
49.	2018	Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
50.	2017/11	Decreased GLP-1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice.
51.	2017/09	Increase of cortisol / ACTH ratio after chronic treatment with liraglutide in subjects with type 2 diabetes mellitus.
52.	2017/08	Werner Syndrome and Diabetes Mellitus Accompanied by Adrenal Cortex Cancer.
53.	2017/05	Advanced breast cancer in a relatively young man with severe obesity and type 2 diabetes mellitus.
54.	2017/05	Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.
55.	2017/03	Beneficial effects of SGLT2 inhibitors for preservation of pancreatic B-cell function and reduction of insulin resistance.
56.	2017/03	Temporal lobe epilepsy associated with GAD autoimmunity.
57.	2016/12	Influence of thyroid volume on the effect of methimazole in Japanese subjects with mild Graves' disease.
58.	2016/11	Association of GA/HbA1c ratio and cognitive impairment in subjects with type 2 diabetes mellitus.
59.	2016/11	Human serum albumin: Possible cause of insulin autoimmune syndrome.
60.	2016/09	Strawberry milk-like blood in a subject with diabetic lipemia: dramatic change to transparent color after insulin therapy.
61.	2016/08	Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic beta-cell function in subjects with type 2 diabetes mellitus.
62.	2016/06	Promising Diabetes Therapy Based on the Molecular Mechanism for Glucose Toxicity: Usefulness of SGLT2 Inhibitors As Well As Incretin-Related Drugs.
63.	2016/05	Case of iliopsoas abscess that was markedly recovered after percutaneous and surgical drainage in a patient with poorly controlled type 2 diabetes.
64.	2016/03	Influence of atherosclerosis-related risk factors on serum hs-CRP levels in type 2 diabetic patients: Comparison of their influence between in obese and non-obese subjects.
65.	2016/02	Hemodialysis Associated with Severe and Unpredictable Hypoglycemia
66.	2016/02	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic B-cells in obese type 2 diabetic db/db mice.
67.	2016	Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better"
68.	2016	Seven-year Observational Study on the Association between Glycemic Control and the New Onset of Macroangiopathy in Japanese Subjects with Type 2 Diabetes
69.	2015/09	Combination of DPP-4 inhibitor and PPARr agonist exerts protective effects on pancreatic beta-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
70.	2015/06	Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes
71.	2015/01	Protective effects of pioglitazone and/or liraglutide on pancreatic B-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes
72.	2015/01	Protective effects of pioglitazone and/or liraglutide on pancreatic B-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes
73.	2015	Case of iliopsoas abscess which was markedly recovered after percutaneous and surgical drainage in a subject with poorly controlled type 2 diabetes.
74.	2015	Dietary restriction preserves the mass and function of pancreatic β cells via cell kinetic regulation and suppression of oxidative/ER stress in diabetic mice
75.	2014	The molecular mechanism by which the short-term intervention of anti-diabetic drugs preserves pancreatic beta-cells in db/db mice : comparison of their straightforward effects between early and advanced stage of diabetes
76.	2013/05	Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
77.	2013/05	Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
Display 5 items
Display all(77)

■ Presentations

1.	2018/06/25	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta cells in obese diabetic db/db mice - ‘‘The earlier and longer, the better’’ （Poster notice，General）
2.	2017/06/11	Long-term administration of dulaglutide does not degrade pancreatic beta-cell GLP-1 receptor expression in non-diabetic and diabetic mice
3.	2017/06/11	Vascular Endothelial PDK1 Plays Pivotal Roles for Maintenance of Pancreatic beta-Cell Function
4.	2017/06/09	SGLT2-Inhibitor Shows a Kidney-Protection Effect through Ketone Body Increase （Abstract Only）
5.	2017/06	Effects of luseogliflozin on intestinal glucose absorption in diabetic mice: - Upregulation of glucose transporter expression by chronic treatment with luseogliflozin - （General）
6.	2016/09/13	Vascular GLP-1 receptor expression is decreased under diabetic conditions -TCF7L2 is a possible regulator of GLP-1 receptor expression in artery- （Speech，General）
7.	2016/06/13	Vascular Endothelial Cell-specific PDK1 Knockout Mice Present Insulin Resistance and Deterioration of Mitochondrial Biogenesis in Muscle under STZ-induced Hyperglycemia （Poster notice，General）
8.	2015/11/21	Vascular GLP-1 receptor expression decreases in subjects with obesity （Poster notice，General）
9.	2015/09/17	Down-regulation of vascular GLP-1 receptor expression in subjects with obesity （Poster notice，General）
10.	2015/06/08	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice （Poster notice，General）
11.	2014/11/22	Protective effect of pioglitazone and liraglutide on B-cells with the progression of diabetic morbidity （Poster notice，General）
12.	2014/11/22	Protective effect of pioglitazone and liraglutide on B-cells with the progression of diabetic morbidity （Poster notice，General）
13.	2013/09/24	Molecular mechanism of protective effect by pioglitazone and/or liraglutide on beta cell damage with the progression of diabetic morbidity （Poster notice，General）
Display 5 items
Display all(13)

■ Professional Organizations

European Association for the Study of Diabetes